Heart rate is also phenotype-coupled: near zero at 1 mg in the obese trial cohort, but +10 bpm or more at the same 1 mg in a leaner body from Phase 1b
Cycle length Typical cycle: 12-16 weeks Minimum for results: 8 weeks Maximum recommended: 6 months continuous use AOD 9604 doesn't require cycling like some peptides
If you specifically want fat loss with minimal other effects, AOD 9604 is cleaner
Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D
The fourth component, GHK-Cu, will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The recommendations of the PCAC are non-binding but noteworthy